Signature Equity Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Signature Equity Partners's BMY Position: Q1 2026 in Review
Signature Equity Partners increased its Bristol-Myers Squibb (BMY) stake by 264% in Q1 2026, buying an estimated $213K and bringing the position to 5,039 shares worth $306K. The position accounts for 0.16% of the portfolio, ranked #133.
Signature Equity Partners first reported a position in BMY in Q4 2025 and has held it in 2 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Signature Equity Partners held 5,039 shares of Bristol-Myers Squibb worth $306K as of Q1 2026.
- Signature Equity Partners bought 3,655 Bristol-Myers Squibb shares in Q1 2026, an estimated $213K.
- Bristol-Myers Squibb made up 0.16% of Signature Equity Partners's portfolio in Q1 2026, its #133 holding.
- Signature Equity Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 2 quarters since.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.